Monoparin (Heparin Sodium)

Heparin sodium binds to antithrombin III, dramatically increasing its ability to inactivate thrombin (factor IIa) and factor Xa. By blocking these key enzymes, the drug interrupts the coagulation cascade, reducing fibrin generation and preventing new clots from forming or existing clots from growing.

The dosage of Monoparin is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and laboratory monitoring. Healthcare professionals determine the appropriate infusion rate or bolus amount to achieve therapeutic anticoagulation.

Safety data for heparin sodium in pregnancy and lactation are limited. It may be used if the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate each case carefully and discuss possible risks with the patient.

To request Monoparin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Monoparin (heparin sodium) is an unfractionated heparin administered intravenously, offering rapid onset and easy titration. Compared with low‑molecular‑weight heparins, it requires more frequent monitoring but is reversible with protamine sulfate and is preferred in settings needing quick adjustment, such as surgery or acute coronary syndromes.

Monoparin should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. If temperature excursions occur, discard the product according to local regulations.

Monoparin is given by intravenous injection or infusion. The route allows rapid distribution throughout the bloodstream. Administration is performed by qualified healthcare personnel in a clinical setting, with dosing adjusted based on activated partial thromboplastin time (aPTT) or anti‑Xa monitoring.

The most serious risks include major bleeding, heparin‑induced thrombocytopenia (HIT), and spinal or epidural hematoma when used with neuraxial techniques. Prompt recognition of these complications and appropriate laboratory monitoring are essential to mitigate harm.

Monoparin is contraindicated in patients with known hypersensitivity to heparin or pork products, active major bleeding, or a history of heparin‑induced thrombocytopenia. Caution is also advised for individuals with severe thrombocytopenia, uncontrolled hypertension, or recent intracranial surgery.